TOTAL: $152.02M
Year to Date: $1,151.37M
Company (Symbol)#*Partner (Country)Amt. (M)Triggering EventDetails (Date)

Antares Pharma Inc. (AMEX:AIS)BioSante Pharmaceuticals Inc. (BPAX)$0.875Milestone paymentAntares received the payment as part of BioSante's marketing agreement with Bradley Pharmaceuticals Inc. for Elestrin, a low-dose transdermal estradiol therapy 12/19)
Bavarian Nordic AS (Denmark; CSE:BAVA)U.S. government$25Milestone paymentBavarian received the payment in relation to its contract to manufacture and deliver 20M doses of its Imvamune smallpox vaccine (12/20)
BioSante Pharmaceuticals Inc. (BPAX)Bradley Pharmaceuticals Inc.$3.5Milestone paymentBioSante received the payment under the terms of its Elestrin (estradiol gel) licensing agreement with Bradley (12/18)
Genmab A/S (Denmark; CSE:GEN)GlaxoSmithKline plc(UK)DKK87.2 ($17)Milestone paymentGenmab received the payment upon treatment of the first patient in a Phase II study of HuMax-CD20 to treat relapsed diffuse large B-cell lymphoma (12/13)
Genmab A/S (Denmark; CSE:GEN)F. Hoffmann-La Roche Ltd. (Switzerland)$0.5Milestone paymentGenmab received the payment for the start of a Phase II trial in recurrent or refractory sarcoma (12/20)
Geron Corp. (GERN)Merck & Co. Inc.$4Milestone paymentGeron received the payment after Merck filed an investigational new drug application with the FDA for a cancer vaccine candidate that targets telomerase (12/12)
Hollis-Eden Pharmaceuticals Inc. (HEPH)Cystic Fibrosis Foundation Therapeutics Inc.$0.645Milestone paymentHollis-Eden has selected Trilex (HE3286) as a drug candidate for lung inflammation associated with cystic fibrosis under an existing collaboration agreement (12/20)
Inovio Biomedical Corp. (AMEX: INO)Merck & Co. Inc.$2Milestone paymentInovio received $2M for the filing of a second investigational new drug application for a DNA-based vaccine using Inovio's MedPulser DNA Delivery System (12/12)
Ligand Pharmaceuticals Inc. (LGND)GlaxoSmithKline plc (UK)$1Milestone paymentLigand received the payment due to GSK's submission of a new drug application for Promacta (eltrombopag olamine) (12/20)
Medarex Inc. (MEDX)Centocor Inc. (unit of Johnson & Johnson)NDMilestone paymentThe payment is related to Centocor's filing of regulatory applications in the U.S. and Europe for CNTO 1275 (ustekinumab) to treat plaque psoriasis (12/7)
Medarex Inc. (MEDX)Amgen Inc. (AMGN)NDMilestone paymentMedarex received the payment for advancing an antibody into human trials (12/18)
Medivir (Sweden; SSE: MVIRB)Tibotec Pharmaceuticals Ltd.€17 ($24.5)Milestone paymentsFor milestones achieved through their collaboration to develop HCV NS3/4A Protease Inhibitors to treat chronic hepatitis C virus infection; one payment is due because Medivir has opted to decline to obtain from Tibotec the marketing rights for an approved pharmaceutical in the Nordic counstries (12/14)
Millennium Pharmaceuticals Inc. (MLNM)Ortho Biotech Products LP (unit of Johnson & Johnson)$40Milestone paymentMillennium will receive the payment due to J&J's achievement of an ex-U.S. sales milestone with the multiple myeloma drug Velcade (bortezomib) (12/28)
Odyssey Thera Inc.*Pfizer Inc.NDMilestone paymentOdyssey received the payments for the creation of an assay panel and the establishment of a system to quantify the biological activity of drug metabolites in living human cells (12/13)
Oncothyreon Inc. (ONTY)Merck KGaA$5Milestone paymentFor the completion of the transfer of certain assays and methodology related to Stimuvax (12/17)
Raven Biotechnologies Inc.*Wyeth Pharmaceuticals Inc.NDMilestone paymentRaven received a milestone payment for Wyeth's exercise of an option to extend its evaluation of selected monoclonal antibodies for potential licensure (12/6)
Rigel Pharmaceuticals Inc. (RIGL)Pfizer Inc.$5Milestone paymentRigel received the payment because Pfizer has begun a Phase I trial of an inhaled formulation of Rigel's small-molecule syk kinase inhibitor, R343, for the treatment of allergic asthma (12/6)
Scynexis Inc.*Merial Ltd.NDMilestone paymentScynexis received the payment as part of its drug discovery collaboration with Scynexis (12/13)
Seattle Genetics Inc. (SGEN)Genentech Inc.(NYSE:DNA)$12Milestone paymentSeattle Genetics will receive a $12M payment for its initiation of a Phase IIb trial of SGN-40 in combination with Rituxan plus chemo-therapy for patients with relapsed or refractory diffuse large B-cell lymphoma (12/7)
Targacept Inc. (TRGT)GlaxoSmithKline plc (UK)$6Milestone paymentTargacept received the payment for the initiation of a Phase I trial of TC-6499 to treat neuropathic pain (12/10)
Transition Therapeutics Inc. (TTHI)Elan Corp. plc (UK; NYSE:ELN)$5Milestone paymentTransition received the payment for the start of a Phase II trial of ELND005 (12/26)

Notes:

# Unless otherwise indicated, shares are traded on the Nasdaq exchange. * Private company. Currency conversions are based on exchange rates at the time of the deal. ND = Not disclosed. AMEX = American Stock Exchange; CSE = Copenhagen Stock Exchange; SSE = Stockholm Stock Exchange.

No Comments